Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 7, 2011, Pages 1270-1280

  Walrand, Stephan ^a   Barone, Raffaella ^a   Pauwels, Stanislas ^a   Jamar, François ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Absorbed dose; Platelet count; Radiometal transchelation; Red marrow uptake

Indexed keywords

DOTATOC Y 86; DOTATOC Y 90; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR; TRACER; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW; CHELATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG UPTAKE; FEMALE; HUMAN; IMAGE ANALYSIS; IN VITRO STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPINE; THROMBOCYTE COUNT;

ADULT; AGED; BIOLOGICAL TRANSPORT; BLOOD PLATELETS; BONE MARROW; CHELATING AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PENTETIC ACID; PLATELET COUNT; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE-BODY IRRADIATION;

EID: 79958035178     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1744-x     Document Type: Article

References (37)

1. B Brans O Linden F Giammarile J Tennvall C Punt 2006 Clinical applications of newer radionuclide therapies Eur J Cancer 42 994 1003 16564689 10.1016/j.ejca.2005.12.020 1:CAS:528:DC%2BD28Xks1eru78%3D
2. G Flux M Bardies M Monsieurs S Savolainen SE Strand M Lassmann, et al. 2006 The impact of PET and SPECT on dosimetry for targeted radionuclide therapy Z Med Phys 16 47 59 16696370
3. G Flux M Bardies C Chiesa M Monsieurs S Savolainen SE Strand, et al. 2007 Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray" Eur J Nucl Med Mol Imaging 34 1699 1700 17565497 10.1007/s00259-007- 0471-9 (Pubitemid 47476925)
4. B Brans L Bodei F Giammarile O Linden M Luster WJ Oyen, et al. 2007 Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray" Eur J Nucl Med Mol Imaging 34 772 786 17268773 10.1007/s00259-006-0338-5 1:STN:280:DC%2BD2s3kvFSktg%3D%3D (Pubitemid 46669368)
5. G Sgouros E Frey R Wahl B He A Prideaux R Hobbs 2008 Three-dimensional imaging-based radiobiological dosimetry Semin Nucl Med 38 321 334 18662554 10.1053/j.semnuclmed.2008.05.008 (Pubitemid 352033565)
6. MG Stabin AB Brill 2008 State of the art in nuclear medicine dose assessment Semin Nucl Med 38 308 320 18662553 10.1053/j.semnuclmed.2008.05.005 (Pubitemid 352033563)
7. R Barone F Borson-Chazot R Valkema S Walrand F Chauvin L Gogou, et al. 2005 Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship J Nucl Med 46 99S 106S 15653658 1:CAS:528:DC%2BD2MXhsVeksLc%3D (Pubitemid 47619025)
8. BW Wessels MW Konijnenberg RG Dale HB Breitz M Cremonesi RF Meredith, et al. 2008 MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response-implications for radionuclide therapy J Nucl Med 49 1884 1899 18927342 10.2967/jnumed.108.053173
9. S Pauwels R Barone S Walrand F Borson-Chazot R Valkema LK Kvols, et al. 2005 Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs J Nucl Med 46 92S 98S 15653657 1:CAS:528:DC%2BD2MXhsVeksLY%3D (Pubitemid 47619024)
10. M Cremonesi M Ferrari L Bodei G Tosi G Paganelli 2006 Dosimetry in peptide radionuclide receptor therapy: a review J Nucl Med 47 1467 1475 16954555 1:CAS:528:DC%2BD28XhtVCmtLbK (Pubitemid 47544933)
11. F Forrer EP Krenning PP Kooij BF Bernard M Konijnenberg WH Bakker, et al. 2009 Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0), Tyr(3)]octreotate Eur J Nucl Med Mol Imaging 36 1138 1146 19247653 10.1007/s00259-009-1072-6 1:CAS:528:DC%2BD1MXmvV2ruro%3D
12. DJ Hnatowich TW Griffin C Kosciuczyk M Rusckowski RL Childs JA Mattis, et al. 1985 Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients J Nucl Med 26 849 858 3861793 1:STN:280:DyaL2M3pt1WjtQ%3D%3D (Pubitemid 16001485)
13. M Cremonesi M Ferrari M Chinol MG Stabin C Grana G Prisco, et al. 1999 Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients Eur J Nucl Med 26 110 120 9933344 10.1007/s002590050366 1:CAS:528:DyaK1MXntFOgtg%3D%3D (Pubitemid 29140023)
14. CF Meares MK Moi H Diril DL Kukis MJ McCall SV Deshpande, et al. 1990 Macrocyclic chelates of radiometals for diagnosis and therapy Br J Cancer Suppl 10 21 26 2383477 1:STN:280:DyaK3czksVGktA%3D%3D (Pubitemid 20226475)
15. C Wu F Virzi DJ Hnatowich 1992 Investigations of N-linked macrocycles for 111In and 90Y labeling of proteins Int J Rad Appl Instrum B 19 239 244 1601676
16. DJ Hnatowich F Virzi PW Doherty 1985 DTPA-coupled antibodies labeled with yttrium-90 J Nucl Med 26 503 509 3989606 1:CAS:528:DyaL2MXktlChtbs%3D (Pubitemid 16192246)
17. JMH de Klerk EB van Dieren AD van het Schip A Hoekstra BA Zonnenberg A van Dijk, et al. 1996 Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts J Nucl Med 37 38 41 8543998 (Pubitemid 26123422)
18. JH Turner PG Claringbold 1991 A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate Eur J Cancer 27 1084 1086 1720321 10.1016/0277-5379(91)90297-Q 1:STN:280:DyaK38%2FmvVKntQ%3D%3D
19. Langham WH. Radiobiological factors in manned space flight. Washington DC: National Academy Press; 1967.
20. C Hindorf G Glatting C Chiesa O Lindén G Flux EANM Dosimetry Committee, et al. 2010 EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry Eur J Nucl Med Mol Imaging 37 1238 1250 20411259 10.1007/s00259-010-1422-4
21. Lassmann M, Chiesa C, Flux G, Bardiès M, EANM Dosimetry Committee, et al. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging 2011;38:192-200. doi: 10.1007/s00259-010-1549-3
22. S Walrand F Jamar I Mathieu J De Camps M Lonneux M Sibomana, et al. 2003 Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86 Eur J Nucl Med Mol Imaging 30 354 361 12634962 10.1007/s00259-002- 1068-y 1:CAS:528:DC%2BD3sXitFGmtLc%3D (Pubitemid 36692859)
23. SH Walrand LR van Elmbt S Pauwels 1996 A non-negative fast multiplicative algorithm in 3D scatter-compensated SPET reconstruction Eur J Nucl Med 23 1521 1526 8854852 10.1007/BF01254478 1:STN:280:DyaK2s%2FgvVShsw%3D%3D (Pubitemid 26379196)
24. M Cristy 1981 Active bone marrow distribution as a function of age in humans Phys Med Biol 26 389 400 7243876 10.1088/0031-9155/26/3/003 1:STN:280:DyaL3M3isVWisA%3D%3D (Pubitemid 11096423)
25. MG Stabin KF Eckerman WE Bolch LG Bouchet PW Patton 2002 Evolution and status of bone and marrow dose models Cancer Biother Radiopharm 17 427 433 12396706 10.1089/108497802760363213 1:STN:280:DC%2BD38njslGgtA%3D%3D
26. WJ Shih C Van Wyk 2003 Tc-99m depreotide SPECT demonstrates photon-deficiency in the thoracic vertebrae after adjunct radiation therapy of lung cancer: correlation with MRI and bone scintigraphy Ann Nucl Med 17 245 248 12846548 10.1007/BF02990029 (Pubitemid 36834438)
27. R Barone S Walrand P Leveque S Pauwels F Jamar 2003 Red marrow toxicity after therapy with radiolabelled somatostatin analogues: a possible role of plasma protein binding Eur J Nucl Med 30 S232 10.1007/s00259-002-1006-z
28. W Hauser HL Atkins KG Nelson P Richards 1970 Technetium-99m DTPA: a new radiopharmaceutical for brain and kidney scanning Radiology 94 679 684 4984092 1:STN:280:DyaE3c7gvVGlsg%3D%3D
29. SM Moerlein MJ Welch 1981 The chemistry of gallium and indium as related to radiopharmaceutical production Int J Nucl Med Biol 8 277 287 6460006 10.1016/0047-0740(81)90034-6 1:CAS:528:DyaL38Xht12lsLw%3D (Pubitemid 12162669)
30. Stern HS, Goodwin DA, Scheffel D, Wagner HN, Kramer HH. In 113m for blood-pool and brain scanning. Nucleonics 1967;25:62-8.
31. H Kroll S Korman E Siegel HE Hart B Rosoff H Spencer D Laszlo 1957 Excretion of yttrium and lanthanum chelates of cyclohexane 1,2-trans diamine tetraacetic acid and diethylenetriamine pentaacetic acid in man Nature 180 919 920 13483559 10.1038/180919b0 1:CAS:528:DyaG1cXit1Wqtg%3D%3D
32. MK Jeffcoat BJ McNeil MA Davis 1978 Indium and iron as tracers for erythroid precursors J Nucl Med 19 496 500 641571 1:CAS:528:DyaE1cXktlyrsrs%3D (Pubitemid 8327543)
33. Goodwin DA, Sundeberg MW, Diamanti C et al. 111In-labeled radiopharmaceuticals and their clinical use. In: Subramanian G, Rhodes BA, Cooper JF, Sood VJ, editors. Radiopharmaceuticals. New York: The Society of Nuclear Medicine; 1975. p. 80.
34. Welch MJ, Welch TJ. Solution chemistry of carrier-free indium. In: Subramanian G, Rhodes BA, Cooper JF, Sood VJ, editors. Radiopharmaceuticals. New York: The Society of Nuclear Medicine; 1975. p. 73.
35. WP Breeman K van der Wansem BF Bernard A van Gameren JL Erion TJ Visser, et al. 2003 The addition of DTPA to [(177)Lu-DOTA(0),Tyr(3)]octreotate prior to administration reduces rat skeleton uptake of radioactivity Eur J Nucl Med Mol Imaging 30 312 315 12552352 10.1007/s00259-002-1054-4 1:CAS:528: DC%2BD3sXms1Cmtg%3D%3D (Pubitemid 36686853)
36. SP Oomen PB van Hennik C Antonissen EG Lichtenauer-Kaligis LJ Hofland SW Lamberts, et al. 2002 Somatostatin is a selective chemoattractant for primitive (CD34+) hematopoietic progenitor cells Exp Hematol 30 116 125 11823046 10.1016/S0301-472X(01)00772-X 1:CAS:528:DC%2BD38XovFKjtg%3D%3D (Pubitemid 34081222)
37. BS Skikne 2008 Serum transferrin receptor Am J Hematol 83 872 875 18821709 10.1002/ajh.21279 1:CAS:528:DC%2BD1cXhsVyntLnJ